A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries
← catalyst calendarSponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-21 | actual | When the study began enrolling |
| Primary completion | 2025-10-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-07 | actual | The whole study's end, after follow-up |
| First posted | 2025-03-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Pain
Intervention
- Drug: Suzetrigine — also filed as VX-548, SUZ, JOURNAVX
Primary outcome
what the primary-completion date above is the date OFProportion of Participants Reporting Good, Very Good, or Excellent on a Patient Global assessment (PGA) for Pain Control at the end of Treatment
measured From Day 3 up to Day 14
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed